Journal of Rheumatic Diseases

Table. 1.

Characteristics of AAV patients at diagnosis and during follow-up (n=101)

AAV patients Values
At the time of diagnosis
Demographic data
Age (yr) 62.0 (21.0)*
Male sex 34 (33.7)
AAV subtypes
MPA 56 (55.4)
GPA 28 (27.7)
EGPA 17 (16.8)
ANCA positivity
MPO-ANCA (or P-ANCA) positivity 73 (72.3)
PR3-ANCA (or C-ANCA) positivity 18 (17.8)
Both ANCA positivity 5 (5.0)
ANCA negativity 15 (14.9)
AAV-specific indices
BVAS 12.0 (11.0)*
FFS 1.0 (1.0)*
Clinical manifestations at diagnosis
General 40 (39.6)
Cutaneous 15 (14.9)
Muco-membranous /Ocular 4 (4.0)
Ear nose throat 48 (47.5)
Pulmonary 67 (66.3)
Cardiovascular 11 (10.9)
Gastrointestinal 4 (4.0)
Renal 61 (60.4)
Nervous 25 (24.8)
Routine laboratory results
Urine protein creatinine ratio 1.42 (2.69)*
Proteinuria 42 (41.5)
Hematuria 49 (48.5)
White blood cell count (/mm3) 8,910.0 (5,857.5)*
Haemoglobin (g/dL) 11.3 (3.5)*
Platelet count (×1,000/mm3) 307.5 (178.0)*
Fasting glucose (mg/dL) 103.0 (28.5)*
Blood urea nitrogen (mg/dL) 17.9 (22.8)*
Serum creatinine (mg/dL) 0.9 (1.8)*
Total protein (g/dL) 6.8 (1.2)*
Serum albumin (g/dL) 3.7 (1.0)*
Alkaline phosphatase (IU/L) 74.0 (35.8)*
Aspartate aminotransferase (IU/L) 18.0 (7.0)*
Alanine aminotransferase (IU/L) 15.0 (13.3)*
Total bilirubin (mg/dL) 0.5 (0.4)*
ESR (mm/hr) 63.5 (68.3)*
CRP (mg/L) 8.0 (69.1)*
Complement
CH50 (U/mL) 60.4 (17.9)*
C3 (mg/dL) 113.0 (37.6)*
C4 (mg/dL) 25.6 (12.4)*
During the follow-up period
Follow-up duration (mo) 26.4 (30.4)*
Poor outcomes during follow-up
All-cause mortality 9 (8.9)
Duration until all-cause mortality (mo) 26.4 (30.4)*
Relapse 31 (30.7)
Duration until relapse (mo) 20.9 (25.5)*
ESRD 20 (19.8)
Duration until ESRD (mo) 20.8 (28.3)*
Medications administered during the follow-up period
Glucocorticoid 96 (95)
Cyclophosphamide 52 (51.5)
Rituximab 19 (18.8)
Azathioprine 61 (60.4)
Mycophenolate mofetil 13 (12.9)
Tacrolimus 6 (5.9)
Methotrexate 9 (8.9)

Values are expressed as the median (interquartile range) or number (%). AAV: ANCA-associated vasculitis, ANCA: antineutrophil cytoplasmic antibody, MPA: microscopic polyangiitis, GPA: granulomatosis with polyangiitis, EGPA: eosinophilic GPA, MPO: myeloperoxidase, P: perinuclear, PR3: proteinase 3, C: cytoplasmic, BVAS: Birmingham Vasculitis Activity Score, FFS: Five-Factor score, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, CH50: total haemolytic complement activity, C3: complement 3, C4: complement 4, ESRD: end-stage renal disease. *Median (interquartile range).

J Rheum Dis 2021;28:85~93 https://doi.org/10.4078/jrd.2021.28.2.85
© J Rheum Dis